PT-141 vs melanotan-2: what makes bremelanotide different

The short version: PT-141 and melanotan-2 are siblings, not twins. Both descend from melanocortin research. Only one made it through FDA review — and for a very different use.

TL;DR

• Both peptides come from melanocortin research and act on the melanocortin receptor family.
• PT-141 (bremelanotide) is selective for MC4 (sexual desire) and is FDA-approved as Vyleesi.
• Melanotan-2 is non-selective, was developed for skin pigmentation, and is not FDA-approved.

What each peptide is

PT-141 (in plain English: a small protein, also called bremelanotide, that activates a specific brain receptor involved in sexual desire) and melanotan-2 (a related small protein that broadly activates several melanocortin receptors, including the one in skin) come from the same line of research. Scientists at the University of Arizona developed an alpha-MSH analog (a synthetic copy of a hormone the body uses to influence pigmentation, appetite, and arousal) in the 1990s. Different research teams modified that compound for different goals.

How they differ

Think of the melanocortin receptor family as five different doorbells (MC1 through MC5). Each rings a different room of the house. Melanotan-2 is a key that fits multiple doorbells at once — including MC1 (skin pigment) and MC4 (desire). PT-141 was refined to ring mostly the MC4 doorbell (Pfaus, Sex Med Rev, 2018). That selectivity matters: more specific signal, fewer off-target effects.

Who asks about it

People come to this comparison after seeing both names on peptide forums and wondering whether they are interchangeable. They are not. The intended use, evidence base, and regulatory status are all different.

What the research says

PT-141 was developed and tested as a sexual-health treatment. Bremelanotide (Vyleesi) was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD — persistent low desire that causes distress) in premenopausal women, with phase 3 trials (RECONNECT) supporting the indication (FDA Vyleesi label, 2019). Melanotan-2 has been studied mostly in the context of skin pigmentation and does not have an FDA-approved indication. Common melanotan-2 reports in the literature describe nausea, blood pressure changes, and atypical mole development.

What to know before considering it

PT-141 has an FDA-approved version (Vyleesi) and is also accessed as a compounded preparation through state-licensed 503A pharmacies — the compounded version is not FDA-approved. FDA removed melanotan-2 (melanotan II) from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, melanotan-2 is not in any FDA 503A category and is not on the 503A bulks list. Anyone considering either compound needs a licensed physician evaluation.

The Halftime POV

These two peptides are often discussed together because they sound alike. Treating them as one compound is a mistake. PT-141 has FDA review, a defined indication, and a published safety profile. Melanotan-2 does not.

Related reading:

• PT-141: how melanocortin signaling affects desire
• Bremelanotide is FDA-approved for women: what Vyleesi treats
• Melanotan II: what the literature says about risks

---

FAQ

Q: What is the difference between PT-141 and melanotan-2? A: Both peptides come from the same melanocortin family and share an early development history. PT-141 (bremelanotide) was refined to selectively activate the MC4 receptor for sexual desire and is FDA-approved as Vyleesi for women with HSDD. Melanotan-2 was developed for tanning and is not FDA-approved.

Q: Is melanotan-2 legal in the U.S.? A: Melanotan-2 is not FDA-approved for any use. FDA removed melanotan-2 (melanotan II) from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 14, 2026, melanotan-2 is not in any FDA 503A category and is not on the 503A bulks list. Online sources sell it as a research chemical, which raises both legal and quality concerns.

Q: Is PT-141 the same as bremelanotide? A: Yes. PT-141 is the development code name. Bremelanotide is the generic drug name. Vyleesi is the brand name of the FDA-approved version for hypoactive sexual desire disorder in premenopausal women.

---

Disclaimer

Melanotan-2 was previously in FDA's Category 2. FDA removed it from Category 2 on April 22, 2026. As of September 14, 2026, it is not in any FDA 503A category and is not on the 503A bulks list. This article is educational and is not medical advice. Halftime Health only prescribes through licensed physicians in states where our partner physicians are credentialed.

Get started

We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.

---

Sources

• FDA — Vyleesi (bremelanotide) Label, 2019
• Pfaus JG et al. — Sexual Medicine Reviews, 2018: The Pharmacology of Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder

---

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.